Clinical trial
A Phase 1, Open-label, Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Subjects With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
NCT02852837 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-label, Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Subjects With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 26, 2016
- Completion date
- December 13, 2019
- Enrollment
- 50 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.